Last updated on May 2019

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer


Brief description of study

The purpose of this study is to determine the benefit and safety of relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels ( 50 ng/dL [1.7 nmol/L] in patients with androgen-sensitive advanced prostate cancer.

Detailed Study Description

This study is an international phase 3 randomized, open-label, parallel group efficacy and safety study to evaluate oral daily relugolix 120 mg in patients with androgen-sensitive advanced prostate cancer who require at least 1 year (48 weeks) of continuous androgen deprivation therapy. Relugolix 120 mg orally once daily or leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in some Asian countries), every 3-months (3-M) by subcutaneous or intramuscular injection will be administered to patients with prostate cancer who require androgen deprivation therapy.

Approximately 1100 patients will be enrolled in this study, including approximately 390 patients with metastatic advanced prostate cancer to support the analysis of the secondary endpoint of time to castration-resistance and 138 Chinese patients (enrolled in China and Taiwan) to support registration in China. The study includes a Screening Period, a Treatment Period of 48 weeks, and a Follow-up Period. Additionally, unscheduled follow-up visit(s) may be arranged for patients with study-related safety concerns as needed. Eligible patients include those with evidence of biochemical relapse (rising PSA) following local primary intervention with curative intent, newly diagnosed metastatic disease (excluding metastases to the brain), and/or advanced localized disease.

Following successful completion of the Screening period study participants will be randomized 2:1 to oral relugolix 120 mg once daily or leuprolide acetate 22.5 mg (or 11.25 mg in some Asian countries) 3-M depot subcutaneous or intramuscular injection and will attend visits monthly (ie, every 4 weeks) where serum testosterone and PSA will be assessed. Safety will be assessed throughout the study by monitoring adverse events, vital signs, physical examinations, clinical laboratory tests, and 12-lead electrocardiograms.

Clinical Study Identifier: NCT03085095

Find a site near you

Start Over

Homewood

Homewood, AL United States
  Connect »

Anchorage

Anchorage, AK United States
  Connect »

Tucson

Tucson, AZ United States
  Connect »

Orange

Orange, CA United States
  Connect »

San Diego

San Diego, CA United States
  Connect »

Denver

Denver, CO United States
  Connect »

Pompano Beach

Pompano Beach, FL United States
  Connect »

Jeffersonville

Jeffersonville, IN United States
  Connect »

Des Moines

Des Moines, IA United States
  Connect »

Wichita

Wichita, KS United States
  Connect »

Towson

Towson, MD United States
  Connect »

Troy

Troy, MI United States
  Connect »

Omaha

Omaha, NE United States
  Connect »

Las Vegas

Las Vegas, NV United States
  Connect »

Brick

Brick, NJ United States
  Connect »

Lawrenceville

Lawrenceville, NJ United States
  Connect »

Albuquerque

Albuquerque, NM United States
  Connect »

Albany

Albany, NY United States
  Connect »

Brooklyn

Brooklyn, NY United States
  Connect »

Garden City

Garden City, NY United States
  Connect »

New York

New York, NY United States
  Connect »

Plainview

Plainview, NY United States
  Connect »

Poughkeepsie

Poughkeepsie, NY United States
  Connect »

Syracuse

Syracuse, NY United States
  Connect »

Durham

Durham, NC United States
  Connect »

Greensboro

Greensboro, NC United States
  Connect »

Winston-Salem

Winston-Salem, NC United States
  Connect »

Cincinnati

Cincinnati, OH United States
  Connect »

MiddleBurg Heights

Middleburg Heights, OH United States
  Connect »

Toledo

Toledo, OH United States
  Connect »

Oklahoma City

Oklahoma City, OK United States
  Connect »

Lancaster

Lancaster, PA United States
  Connect »

Myrtle Beach

Myrtle Beach, SC United States
  Connect »

Nashville

Nashville, TN United States
  Connect »

Dallas

Dallas, TX United States
  Connect »

San Antonio

San Antonio, TX United States
  Connect »

Virginia Beach

Virginia Beach, VA United States
  Connect »

Camperdown

Camperdown, Australia
  Connect »

Darlinghurst

Darlinghurst, Australia
  Connect »

Tweed Heads

Tweed Heads, Australia
  Connect »

Wahroonga

Wahroonga, Australia
  Connect »

Westmead

Westmead, Australia
  Connect »

Cairns

Cairns, Australia
  Connect »

Redcliffe

Redcliffe, Australia
  Connect »

Geelong

Geelong, Australia
  Connect »

Herston

Herston, Australia
  Connect »

Linz

Linz, Austria
  Connect »

Salzburg

Salzburg, Austria
  Connect »

Edegem

Edegem, Belgium
  Connect »

Gent

Gent, Belgium
  Connect »

Leuven

Leuven, Belgium
  Connect »

Brussels

Brussels, Belgium
  Connect »

Kortrijk

Kortrijk, Belgium
  Connect »

Itabuna

Itabuna, Brazil
  Connect »

Salvador

Salvador, Brazil
  Connect »

Curitiba

Curitiba, Brazil
  Connect »

Teresina

Teresina, Brazil
  Connect »

Natal

Natal, Brazil
  Connect »

Iju

Ijuí, Brazil
  Connect »

Passo Fundo

Passo Fundo, Brazil
  Connect »

Porto Alegre

Porto Alegre, Brazil
  Connect »

Joinville

Joinville, Brazil
  Connect »

S o Jos Do Rio Preto

São José Do Rio Preto, Brazil
  Connect »

S o Paulo

São Paulo, Brazil
  Connect »

Calgary

Calgary, AB Canada
  Connect »

Vancouver

Vancouver, BC Canada
  Connect »

Halifax

Halifax, NS Canada
  Connect »

Hamilton

Hamilton, ON Canada
  Connect »

London

London, ON Canada
  Connect »

Montreal

Montréal, QC Canada
  Connect »

Sherbrooke

Sherbrooke, QC Canada
  Connect »

Toronto

Toronto, QC Canada
  Connect »

Quebec

Quebec, QC Canada
  Connect »

Nanjing

Nanjing, China
  Connect »

Changchun

Chang chun, China
  Connect »

Shanghai

Shanghai, China
  Connect »

Beijing

Beijing, China
  Connect »

Alborg

Aalborg, Denmark
  Connect »

Aarhus

Aarhus, Denmark
  Connect »

Copenhagen

Copenhagen, Denmark
  Connect »

Herlev

Herlev, Denmark
  Connect »

Vejle

Vejle, Denmark
  Connect »

Helsinki

Helsinki, Finland
  Connect »

Seinajoki

Seinäjoki, Finland
  Connect »

Tampere

Tampere, Finland
  Connect »

Turku

Turku, Finland
  Connect »

Strasbourg

Strasbourg, France
  Connect »

Marseille

Marseille, France
  Connect »

Lille

Lille, France
  Connect »

Pierre Benite

Pierre-Bénite, France
  Connect »

Creteil

Créteil, France
  Connect »

Hyeres

Hyères, France
  Connect »

Lyon

Lyon, France
  Connect »

Nimes

Nîmes, France
  Connect »

Poitiers

Poitiers, France
  Connect »

Emmendingen

Emmendingen, Germany
  Connect »

Planegg

Planegg, Germany
  Connect »

Braunschweig

Braunschweig, Germany
  Connect »

Dresden

Dresden, Germany
  Connect »

Hamburg

Hamburg, Germany
  Connect »

Lubeck

Lübeck, Germany
  Connect »

Munster

Münster, Germany
  Connect »

Meldola

Meldola, Italy
  Connect »

Rome

Rome, Italy
  Connect »

Cremona

Cremona, Italy
  Connect »

Candiolo

Candiolo, Italy
  Connect »

Orbassano

Orbassano, Italy
  Connect »

Arezzo

Arezzo, Italy
  Connect »

Milano

Milano, Italy
  Connect »

Pavia

Pavia, Italy
  Connect »

Kanazawa-shi

Kanazawa-shi, Japan
  Connect »

Sendai

Sendai, Japan
  Connect »

Suita

Suita, Japan
  Connect »

Iju

Ijuí, Brazil
  Connect »

S o Jos Do Rio Preto

São José Do Rio Preto, Brazil
  Connect »

S o Paulo

São Paulo, Brazil
  Connect »

Montreal

Montréal, QC Canada
  Connect »

Seinajoki

Seinäjoki, Finland
  Connect »

Pierre Benite

Pierre-Bénite, France
  Connect »

Creteil

Créteil, France
  Connect »

Hyeres

Hyères, France
  Connect »

Nimes

Nîmes, France
  Connect »

Lubeck

Lübeck, Germany
  Connect »

Munster

Münster, Germany
  Connect »

Busan

Busan, Korea, Republic of
  Connect »

Seongnam

Seongnam, Korea, Republic of
  Connect »

Bratislava

Bratislava, Slovakia
  Connect »

Hiroshima

Hiroshima, Japan
  Connect »

Maebashi-shi

Maebashi, Japan
  Connect »

Nagasaki-shi

Nagasaki, Japan
  Connect »

Osaka

Osaka, Japan
  Connect »

Sapporo

Sapporo, Japan
  Connect »

Tokyo

Tokyo, Japan
  Connect »

Hwasun-gun

Hwasun, Korea, Republic of
  Connect »

Seoul

Seoul, Korea, Republic of
  Connect »

Maastricht

Maastricht, Netherlands
  Connect »

Sneek

Sneek, Netherlands
  Connect »

Dunedin

Dunedin, New Zealand
  Connect »

Canterbury

Christchurch, New Zealand
  Connect »

Tauranga

Tauranga, New Zealand
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.